ARCHIVES

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

This article is from The Cancer Letter archive.

Vol. 29 No. 9 | September 29, 2006

Download PDF Visit The Full Archive

Related Articles

Omnibus bill recissions would cut $28 million from NCI FY04 budget.

January 9, 2004

HHS System Of Misconduct investigation Not Suited For Clinical Trials, Broder Says

November 11, 1994

Opposition To Lederberg May Have Caused Delay In Panel Appointments; FY 19809 Funds Held Up

October 5, 1979

In Brief: Kennedy, Waxman May Agree On Simple Extension Of Biomedical Research Authority, Including NCI

November 21, 1980

IOM Panel Considering NCI Approach To Research In Minorities, Underserved

June 19, 1998

News Analysis: Generic Drug Industry’s Efforts to Eliminate Shortages Raises Antitrust Law Questions

April 27, 2012